CHMP issues positive opinion on new schedule for Sanofi Pasteur's Hexyon
The European Medicines agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on an additional schedule of administration for Hexyon, (DTaP-IPV-Hep B-Hib).
Hexyon, manufactured by Sanofi Pasteur, the vaccines division of French drug major Sanofi (Euronext: SAN), protects infants against: diphtheria, tetanus, whooping cough, hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b. It has been recommended for two doses in primary vaccination and one as a booster dose. The European countries recommending the ‘2+1’ schedule for infant vaccination include France, Italy, Austria, Denmark, Norway and Sweden. It is already recommended in other European countries using a ‘3+1’ schedule.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze